Aberdeen Group plc Boosts Holdings in Vaxcyte, Inc. $PCVX

Aberdeen Group plc raised its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 70.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 722,793 shares of the company’s stock after acquiring an additional 297,886 shares during the quarter. Aberdeen Group plc owned approximately 0.55% of Vaxcyte worth $26,035,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of PCVX. HighVista Strategies LLC boosted its position in shares of Vaxcyte by 1.1% in the second quarter. HighVista Strategies LLC now owns 33,457 shares of the company’s stock worth $1,088,000 after purchasing an additional 355 shares during the period. Arizona State Retirement System boosted its holdings in Vaxcyte by 1.6% in the 3rd quarter. Arizona State Retirement System now owns 34,333 shares of the company’s stock worth $1,237,000 after buying an additional 543 shares during the period. Atria Investments Inc increased its stake in Vaxcyte by 11.1% in the 2nd quarter. Atria Investments Inc now owns 6,816 shares of the company’s stock worth $222,000 after buying an additional 683 shares in the last quarter. Hsbc Holdings PLC raised its holdings in Vaxcyte by 4.1% during the second quarter. Hsbc Holdings PLC now owns 19,216 shares of the company’s stock valued at $628,000 after acquiring an additional 755 shares during the period. Finally, Virtus Investment Advisers LLC raised its holdings in Vaxcyte by 45.8% during the second quarter. Virtus Investment Advisers LLC now owns 2,729 shares of the company’s stock valued at $89,000 after acquiring an additional 857 shares during the period. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Down 1.4%

PCVX opened at $53.33 on Wednesday. The business has a fifty day moving average of $49.26 and a 200 day moving average of $42.51. The stock has a market cap of $6.98 billion, a P/E ratio of -11.02 and a beta of 1.33. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $85.22.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on PCVX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Friday, January 9th. Needham & Company LLC raised their target price on shares of Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Leerink Partners set a $77.00 price target on shares of Vaxcyte and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. BTIG Research reaffirmed a “buy” rating and issued a $85.00 target price on shares of Vaxcyte in a report on Monday, November 10th. Finally, Guggenheim reiterated a “buy” rating and issued a $116.00 target price on shares of Vaxcyte in a research report on Monday, February 2nd. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $93.83.

Insider Activity at Vaxcyte

In other Vaxcyte news, SVP Elvia Cowan sold 11,623 shares of the company’s stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of $47.92, for a total value of $556,974.16. Following the sale, the senior vice president directly owned 14,534 shares of the company’s stock, valued at approximately $696,469.28. This represents a 44.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Harpreet S. Dhaliwal sold 9,743 shares of the company’s stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total value of $454,900.67. Following the completion of the sale, the insider owned 23,928 shares in the company, valued at $1,117,198.32. The trade was a 28.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.10% of the company’s stock.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.